225 related articles for article (PubMed ID: 12723505)
41. Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial.
Araya T; Kasahara K; Kimura H; Shibata K; Kita T; Shirasaki H; Hara J; Yoshimi Y; Sone T; Oribe Y; Nobata K; Nishi K; Fujimura M; Nakao S;
Lung Cancer; 2007 Jun; 56(3):371-6. PubMed ID: 17300851
[TBL] [Abstract][Full Text] [Related]
42. Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Pedersen AG
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-64-S7-68. PubMed ID: 9194483
[TBL] [Abstract][Full Text] [Related]
43. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Fossella FV; Lippman SM; Shin DM; Tarassoff P; Calayag-Jung M; Perez-Soler R; Lee JS; Murphy WK; Glisson B; Rivera E; Hong WK
J Clin Oncol; 1997 Jan; 15(1):310-6. PubMed ID: 8996158
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine pulmonary toxicity: CT features.
Boiselle PM; Morrin MM; Huberman MS
J Comput Assist Tomogr; 2000; 24(6):977-80. PubMed ID: 11105721
[TBL] [Abstract][Full Text] [Related]
45. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine-associated autonomic neuropathy.
Dormann AJ; Grünewald T; Wigginghaus B; Huchzermeyer H
Lancet; 1998 Feb; 351(9103):644. PubMed ID: 9500323
[No Abstract] [Full Text] [Related]
47. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
48. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
Gatzemeier U; Shepherd FA; Le Chevalier T; Weynants P; Cottier B; Groen HJ; Rosso R; Mattson K; Cortes-Funes H; Tonato M; Burkes RL; Gottfried M; Voi M
Eur J Cancer; 1996 Feb; 32A(2):243-8. PubMed ID: 8664035
[TBL] [Abstract][Full Text] [Related]
49. Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer.
Chen YM; Liu JM; Tsai CM; Whang-Peng J; Perng RP
J Clin Oncol; 1996 May; 14(5):1743-4. PubMed ID: 8622097
[No Abstract] [Full Text] [Related]
50. Severe pulmonary toxicity in a patient treated with gemcitabine.
Rosado MF; Kett DH; Schein RM; Baraona FJ; Sridhar KS
Am J Clin Oncol; 2002 Feb; 25(1):31-3. PubMed ID: 11823691
[TBL] [Abstract][Full Text] [Related]
51. [Interstitial lung disease in a patient given gemcitabine].
Hammerer V; Schmitz N; Pauli G; Quoix E
Rev Pneumol Clin; 2002 Feb; 58(1):23-6. PubMed ID: 11981501
[TBL] [Abstract][Full Text] [Related]
52. Veno-occlusive disease of the liver induced by gemcitabine.
Dobbie M; Hofer S; Oberholzer M; Herrmann R
Ann Oncol; 1998 Jun; 9(6):681. PubMed ID: 9681086
[No Abstract] [Full Text] [Related]
53. Gemcitabine for lung cancer.
Drug Ther Bull; 1996 Sep; 34(9):71-2. PubMed ID: 8885499
[No Abstract] [Full Text] [Related]
54. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
55. Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
Umemura S; Yamane H; Suwaki T; Katoh T; Yano T; Shiote Y; Takigawa N; Kiura K; Kamei H
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1469-75. PubMed ID: 21818557
[TBL] [Abstract][Full Text] [Related]
56. Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy.
Gurumurthy M; Koh P; Singh R; Bhide A; Satodia P; Hocking M; Anbarasu A; Wood LE
J Perinatol; 2009 Jan; 29(1):63-5. PubMed ID: 19112460
[TBL] [Abstract][Full Text] [Related]
57. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
Sandler AB; Nemunaitis J; Denham C; von Pawel J; Cormier Y; Gatzemeier U; Mattson K; Manegold C; Palmer MC; Gregor A; Nguyen B; Niyikiza C; Einhorn LH
J Clin Oncol; 2000 Jan; 18(1):122-30. PubMed ID: 10623702
[TBL] [Abstract][Full Text] [Related]
58. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine: safety profile unaffected by starting dose.
Martin C; Pollera CF
Int J Clin Pharmacol Res; 1996; 16(1):9-18. PubMed ID: 9001925
[TBL] [Abstract][Full Text] [Related]
60. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
